Peripherally Applied Synthetic Tetrapeptides HAEE and RADD Slow Down the Development of Cerebral β-Amyloidosis in AβPP/PS1 Transgenic Mice

Article type: Short Communication

Authors: Tsvetkov, Philipp O.^{a; b} | Cheglakov, Ivan B.^c | Ovsepyan, Armen A.^c | Mediannikov, Oleg Y.^d | Morozov, Alexander O.^d | Telegin, Georgy B.^c | Kozin, Sergey A.^{d; *}

Affiliations: [a] Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Faculté de Pharmacie, Marseille, France | [b] The Institute of General Pathology and Pathophysiology, Moscow, Russia | [c] Branch of Shemyakin and Ovchinnikov Institute of bioorganic chemistry of Russian academy of sciences, Pushchino, Russia | [d] Kimonella Ventures Ltd., Limassol, Cyprus

Correspondence: [*] Correspondence to: Sergey A. Kozin, PhD, Kimonella Ventures Ltd., 205, Makarios III Avenue, Victory House, CY3030, Limassol, Cyprus. Tel.: +7 498 309 06 81; kozinsa@gmail.com

Abstract: Two tetrapeptides, HAEE and RADD, which are ionic-complementary to the primary zinc recognition site of amyloid-β (Aβ), have been reported to inhibit zinc-induced dimerization of the Aβ metal-binding domain and slow Aβ aggregation in vitro. In the present study, we investigate the impact of HAEE and RADD on the development of cerebral β-amyloidosis in a mouse model of Alzheimer’s disease. We have found chronic intravenous administration of each peptide results in significant decrease of amyloid plaque burden in the treated mice.

Keywords: Alzheimer’s disease, amyloid-β, mouse models, protein aggregation in vivo

DOI: 10.3233/JAD-150031

Journal: Journal of Alzheimer's Disease, vol. 46, no. 4, pp. 849-853, 2015